These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
639 related articles for article (PubMed ID: 28056988)
21. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. Zisman A; Wieder JA; Pantuck AJ; Chao DH; Dorey F; Said JW; Gitlitz BJ; deKernion JB; Figlin RA; Belldegrun AS J Urol; 2003 Mar; 169(3):909-16. PubMed ID: 12576811 [TBL] [Abstract][Full Text] [Related]
22. Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. Rodriguez Faba O; Linares E; Tilki D; Capitanio U; Evans CP; Montorsi F; Martínez-Salamanca JI; Libertino J; Gontero P; Palou J Eur Urol Focus; 2018 Apr; 4(3):435-441. PubMed ID: 28753848 [TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes after cytoreductive nephrectomy and thrombectomy of patients with metastatic renal cell carcinoma with venous tumor thrombus: a retrospective study from a large Chinese center. Chen K; Liu Z; Li Y; Zhao X; Zhang Y; Bi H; Wang G; Liu C; Tian X; Zhang H; Ma L; Zhang S World J Surg Oncol; 2023 Jun; 21(1):170. PubMed ID: 37280590 [TBL] [Abstract][Full Text] [Related]
24. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
25. Treatment of renal cell carcinoma with a level III or level IV inferior vena cava thrombus using cardiopulmonary bypass and deep hypothermic circulatory arrest. Chen YH; Wu XR; Hu ZL; Wang WJ; Jiang C; Kong W; Chen W; Xue W; Liu DM; Huang YR World J Surg Oncol; 2015 Apr; 13():159. PubMed ID: 25897659 [TBL] [Abstract][Full Text] [Related]
26. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis. Hong X; Li F; Tang K; Pang S; Lin G; Li S; Bao J; Tan W Int Urol Nephrol; 2016 Jun; 48(6):967-75. PubMed ID: 26861063 [TBL] [Abstract][Full Text] [Related]
27. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy. Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986 [TBL] [Abstract][Full Text] [Related]
28. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544 [TBL] [Abstract][Full Text] [Related]
29. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Cost NG; Delacroix SE; Sleeper JP; Smith PJ; Youssef RF; Chapin BF; Karam JA; Culp S; Abel EJ; Brugarolas J; Raj GV; Sagalowsky AI; Wood CG; Margulis V Eur Urol; 2011 Jun; 59(6):912-8. PubMed ID: 21367518 [TBL] [Abstract][Full Text] [Related]
30. Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus. Lambert EH; Pierorazio PM; Shabsigh A; Olsson CA; Benson MC; McKiernan JM Urology; 2007 Jun; 69(6):1054-8. PubMed ID: 17572185 [TBL] [Abstract][Full Text] [Related]
31. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy. Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948 [TBL] [Abstract][Full Text] [Related]
32. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. Ciancio G; Manoharan M; Katkoori D; De Los Santos R; Soloway MS Eur Urol; 2010 Apr; 57(4):667-72. PubMed ID: 19560258 [TBL] [Abstract][Full Text] [Related]
33. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581 [TBL] [Abstract][Full Text] [Related]
34. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. Lenis AT; Burton CS; Golla V; Pooli A; Faiena I; Johnson DC; Salmasi A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K Urol Oncol; 2019 Sep; 37(9):577.e9-577.e16. PubMed ID: 30930099 [TBL] [Abstract][Full Text] [Related]
36. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Peyton CC; Abel EJ; Chipollini J; Boulware DC; Azizi M; Karam JA; Margulis V; Master VA; Matin SF; Raman JD; Sexton WJ; Wood CG; Spiess PE Eur Urol Focus; 2020 Jan; 6(1):104-111. PubMed ID: 30206003 [TBL] [Abstract][Full Text] [Related]
37. Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: single-center experience. Kondo T; Ikezawa E; Takagi T; Kobayashi H; Hashimoto Y; Iizuka J; Omae K; Yoshida K; Tanabe K Int J Urol; 2013 Nov; 20(11):1072-7. PubMed ID: 23421632 [TBL] [Abstract][Full Text] [Related]
38. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database. Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149 [TBL] [Abstract][Full Text] [Related]
39. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741 [TBL] [Abstract][Full Text] [Related]
40. Symptomatic Venous Thromboembolism is Associated with Inferior Survival among Patients Undergoing Nephrectomy with Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. Shah PH; Thompson RH; Boorjian SA; Lohse CM; Lyon TD; Shields RC; Froehling D; Leibovich BC; Viers BR J Urol; 2018 Sep; 200(3):520-527. PubMed ID: 29709665 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]